Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study

Out of 302 AIDS-related lymphoma (ARL) patients enrolled in the German ARL cohort study, 18 patients had plasmablastic lymphoma (PBL). Twelve out of 18 patients (67%) have died with a median survival of 4 months (range 0-11 months). In univariate analysis, an intermediate or high international progn...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	AIDS (London) 2013-03, Vol.27 (5), p.842-845
Hauptverfasser:	Schommers, Philipp, Wyen, Christoph, Hentrich, Marcus, Gillor, Daniel, Zoufaly, Alexander, Jensen, Bjoern, Bogner, Johannes R, Thoden, Jan, Wasmuth, Jan C, Fätkenheuer, Gerd, Hoffmann, Christian
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged AIDS/HIV Analysis of Variance Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antiretroviral Therapy, Highly Active - methods Cohort Studies Germany HIV Infections - complications HIV Infections - drug therapy HIV Infections - mortality Humans Lymphoma, AIDS-Related - drug therapy Lymphoma, AIDS-Related - etiology Lymphoma, AIDS-Related - mortality Lymphoma, Non-Hodgkin - drug therapy Lymphoma, Non-Hodgkin - etiology Lymphoma, Non-Hodgkin - mortality Male Middle Aged Prognosis Prospective Studies Severity of Illness Index
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Out of 302 AIDS-related lymphoma (ARL) patients enrolled in the German ARL cohort study, 18 patients had plasmablastic lymphoma (PBL). Twelve out of 18 patients (67%) have died with a median survival of 4 months (range 0-11 months). In univariate analysis, an intermediate or high international prognostic index score was associated with a significantly lower overall survival and progression-free survival. The predominant cause of death was progressive lymphoma (67%). Our data indicate that the outcome of AIDS-related PBL is still very poor.
ISSN:	0269-9370 1473-5571
DOI:	10.1097/QAD.0b013e32835e069d